Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.
| Revenue (TTM) | $3.22B |
| Gross Profit (TTM) | $1.83B |
| EBITDA | $286.00M |
| Operating Margin | 0.47% |
| Return on Equity | -8.66% |
| Return on Assets | 1.73% |
| Revenue/Share (TTM) | $12.22 |
| Book Value | $12.87 |
| Price-to-Book | 1.59 |
| Price-to-Sales (TTM) | 1.75 |
| EV/Revenue | 1.73 |
| EV/EBITDA | 92.94 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 16.60% |
| Shares Outstanding | $281.35M |
| Float | $28.47M |
| % Insiders | 89.92% |
| % Institutions | 13.54% |
Volatility is currently contracting
NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Sheila Denton has been named General Counsel & Corporate Secretary.
MiniMed Group, Inc. (MMED) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Medtronic shareholders can exchange their Medtronic ordinary shares for shares of MiniMed Provides Medtronic shareholders with option for a generally tax-free exchange for U.S. federal income tax purposes GALWAY, Ireland, Sept. 14, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced that it has commenced an exchange offer to split off at least 80.1% of the shares of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED).
NORTHRIDGE, Calif., Sept. 14, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) announced that it has filed a Form S-4 Registration Statement today with the Securities and Exchange Commission (the "SEC") in connection with Medtronic plc's ("Medtronic"; NYSE: MDT) offer to exchange up to 225,361,295 shares of MiniMed common stock, representing 80.1% of the total outstanding shares of MiniMed common stock, for outstanding Medtronic ordinary shares that are validly tendered and not validly withdrawn.
A new product introduction helped lift the top line. It seems there's more where that came from, with new product introductions scheduled over the coming months.
MiniMed's pumps support the demand for more CGMs and consumables. This creates a recurring revenue base for MMED. MMED's Q1 FY2027 also mentioned newer sensors and a dosing algorithm that should increase its value proposition for customers as well. Their latest quarter was cash flow intensive, but longer-term management expects their cash flow to improve as temporary separation costs roll off.
MiniMed Group NASDAQ: MMED reported fiscal 2027 first-quarter revenue of $843 million, with organic revenue growth of 15.8%, as demand for its newer insulin-delivery and continuous glucose monitoring products supported growth in the United States and international markets.
Strong start to fiscal year with net sales of $843 million growing 17% as reported and 16% organic U.S. net sales growth accelerated to 13%; continued robust international net sales growth of 18% as reported, 17% organic Advanced global pipeline ahead of schedule with FDA submission for MiniMed Fit™, CE Mark for MiniMed Flex™, Vivera™ FCL U.S. pivotal trial enrollment completion, and IDE approval for next-gen extended wear MiniMed sensor Raises fiscal year 2027 organic revenue growth guidance NORTHRIDGE, Calif., Sept. 1, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today reported financial results for its first quarter (Q1) of fiscal year 2027 (FY27), ended July 31, 2026.
NORTHRIDGE, Calif., Aug. 25, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that management will participate in fireside chats at the following investor conferences: 21st Annual Wells Fargo Healthcare Conference Tuesday, September 8, 2026, at 3:00 p.m.
MMED's MiniMed Flex is now shipping in the U.S. with Abbott's 15-day Instinct sensor, pairing discreet app control with automated insulin delivery.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MMED and any ticker you trade — then tracks every position and per-strategy win rate.
